Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies

NCT03233139 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies

Interventions

DRUG: Cemiplimab
DRUG: Ipilimumab
DRUG: Platinum-doublet chemotherapy
DRUG: Gemcitabine
DRUG: Pemetrexed
DRUG: Paclitaxel
DRUG: Fianlimab

Sponsor

Regeneron Pharmaceuticals